Academic Pathology, Division of Cancer and Stem Cells, School of Medicine, The University of Nottingham, Nottingham, UK.
Histopathology department, South Egypt Cancer Institute, Asyut University, Asyut, Egypt.
Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20.
Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and guidelines for their assessment have been published. This study aims to evaluate: (a) methods of TILs assessment, and (b) their prognostic significance in breast ductal carcinoma in situ (DCIS). Hematoxylin and eosin sections from two clinically annotated DCIS cohorts; a training set (n = 150 pure DCIS) and a validation set (n = 666 comprising 534 pure DCIS and 132 cases wherein DCIS and invasive breast carcinoma were co-existent) were assessed. Seven different scoring methods were applied to the training set to identify the most optimal reproducible method associated with strongest prognostic value. Among different methods, TILs touching ducts' basement membrane or away from it by one lymphocyte cell thickness provided the strongest significant association with outcome and highest concordance rate [inter-cluster correlation coefficient = 0.95]. Assessment of periductal TILs at increasing distances from DCIS (0.2 , 0.5 , and 1 mm) as well as percent of stromal TILs were practically challenging and showed lower concordance rates than touching TILs. TILs hotspots and lymphoid follicles did not show prognostic significance. Within the pure DCIS validation set, dense TILs were associated with younger age, symptomatic presentation, larger size, higher nuclear grade, comedo necrosis and estrogen receptor negativity as well as shorter recurrence-free interval (p = 0.002). In multivariate survival analysis, dense TILs were independent predictor of shorter recurrence-free interval (p = 0.002) in patients treated with breast conservation. DCIS associated with invasive carcinoma showed denser TILs than pure DCIS (p = 9.0 × 10). Dense TILs is an independent prognostic variable in DCIS. Touching TILs provides a reproducible method for their assessment that can potentially be used to guide management.
肿瘤浸润淋巴细胞(TILs)为浸润性乳腺癌提供预后价值,并且已经发布了评估 TILs 的指南。本研究旨在评估:(a)TILs 评估方法;(b)其在乳腺导管原位癌(DCIS)中的预后意义。对两个临床注释的 DCIS 队列的苏木精和伊红切片进行评估;一个训练集(n=150 例纯 DCIS)和一个验证集(n=666 例,包括 534 例纯 DCIS 和 132 例 DCIS 与浸润性乳腺癌共存的病例)。在训练集中应用了七种不同的评分方法,以确定与最强预后价值相关的最具可重复性的方法。在不同的方法中,TILs 触及导管基底膜或与其相差一个淋巴细胞细胞厚度,与结果的关联最强且一致性最高[聚类间相关系数=0.95]。评估从 DCIS 增加距离的周围 TILs(0.2、0.5 和 1mm)以及间质 TILs 的百分比在实践中具有挑战性,并且与触及 TILs 的一致性较低。TILs 热点和淋巴滤泡与预后无关。在纯 DCIS 验证集中,密集的 TILs与年轻、有症状的表现、较大的肿瘤大小、更高的核分级、粉刺样坏死和雌激素受体阴性以及无复发生存期较短相关(p=0.002)。在多变量生存分析中,密集的 TILs是接受保乳治疗的患者无复发生存期较短的独立预测因子(p=0.002)。与 DCIS 相关的浸润性癌比纯 DCIS 有更密集的 TILs(p=9.0×10)。密集的 TILs是 DCIS 的独立预后变量。触及 TILs 提供了一种可重复的评估方法,可能有助于指导管理。